ANDA 201530, held by Extrovis. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 201530 (Methotrexate Sodium Preservative Free), held by Extrovis, was first approved by FDA on Mar 29, 2012, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate Sodium Preservative FreeEQ 1GM BASE/40ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Discontinued |
| Jul 13, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 13, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 5, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 29, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters